Otsuka Pharmaceutical Co., Ltd.
Clinical trials sponsored by Otsuka Pharmaceutical Co., Ltd., explained in plain language.
-
New schizophrenia drug tested for Year-Long safety
Disease control Recruiting nowThis study is testing a new medication called SEP-363856 in 100 adults with stable schizophrenia. Participants will take either 75 mg or 100 mg daily for 52 weeks to see if it is safe and tolerable. The goal is to manage symptoms, not to cure the condition.
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 05:30 UTC
-
New ADHD pill tested for Year-Long safety in kids
Disease control Recruiting nowThis study tests the safety of a daily medication called EB-1020 for children and teenagers with ADHD over 52 weeks. About 180 participants in Japan and China will take the drug once a day. Researchers will monitor side effects to see if long-term use is safe.
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New ADHD pill for kids tested in Japan-China joint trial
Symptom relief Recruiting nowThis study tests whether a once-daily capsule called EB-1020 can safely reduce ADHD symptoms in children and adolescents aged 6 to 17. About 315 participants will receive either a low dose, a high dose, or a placebo for 6 weeks. The main goal is to see if symptoms improve using a…
Phase: PHASE2, PHASE3 • Sponsor: Otsuka Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated May 14, 2026 12:05 UTC
-
Lupus drug under the microscope: Real-World safety study launches
Knowledge-focused Recruiting nowThis study watches 400 people with lupus nephritis who are starting LUPKYNIS to see how safe the drug is in real life and how well it works. Researchers will collect information on side effects and other safety events. The goal is to learn more about the drug's effects outside of…
Sponsor: Otsuka Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated May 13, 2026 15:58 UTC